To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
GeneNews Granted U.S. Patent for Chagas Disease Based on Sentinel Principle™ Platform
Read time: Less than a minute
GeneNews Limited has announced it has been granted U.S. Patent No. 7,473,528 entitled "Method for the detection of Chagas disease related gene transcripts in blood".
This patent protects the Company's discovery of a blood biomarker-based method of testing for Chagas disease, a serious and potentially fatal disease resulting from parasitic infection. Chagas disease is a significant public health issue affecting more than 11 million people worldwide each year.
"The Sentinel Principle™ technology is the basis of not only this issued patent but also for the personalized health management system we are developing which applies genomic information to monitor and address health concerns on an individualized basis," stated Dr. Choong-Chin Liew, the discoverer of the Sentinel Principle and Co-founder, Chief Scientist and Director of GeneNews.
"GeneNews has a broad array of pending patent applications in diverse disease areas including oncology, cardiovascular, neurological and inflammatory conditions," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews.
"This is our first patent issuance based on our Sentinel Principle platform technology and represents an important initial milestone to realize commercial value from our pipeline of discoveries." The Company currently has five issued patents and more than 70 pending patent applications, the majority of which are based on the application of the Sentinel Principle.
This patent protects the Company's discovery of a blood biomarker-based method of testing for Chagas disease, a serious and potentially fatal disease resulting from parasitic infection. Chagas disease is a significant public health issue affecting more than 11 million people worldwide each year.
"The Sentinel Principle™ technology is the basis of not only this issued patent but also for the personalized health management system we are developing which applies genomic information to monitor and address health concerns on an individualized basis," stated Dr. Choong-Chin Liew, the discoverer of the Sentinel Principle and Co-founder, Chief Scientist and Director of GeneNews.
"GeneNews has a broad array of pending patent applications in diverse disease areas including oncology, cardiovascular, neurological and inflammatory conditions," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews.
"This is our first patent issuance based on our Sentinel Principle platform technology and represents an important initial milestone to realize commercial value from our pipeline of discoveries." The Company currently has five issued patents and more than 70 pending patent applications, the majority of which are based on the application of the Sentinel Principle.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
